サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1695928

骨粗鬆症治療薬の世界市場：2034年までの市場の機会と戦略

Osteoporosis Drugs Global Market Opportunities And Strategies To 2034

出版日
ページ情報
英文 317 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
骨粗鬆症治療薬の世界市場：2034年までの市場の機会と戦略
出版日: 2025年03月20日
発行: The Business Research Company
ページ情報: 英文 317 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の骨粗鬆症治療薬の市場規模は、2019年に114億3,616万米ドルとなりました。同市場は、2024年までCAGR2.00%以上で成長しています。

実績期間において、健康保険の拡大は骨粗鬆症治療薬市場の成長を支えました。健康保険はヘルスケアコストを削減し、骨粗鬆症治療薬の購入しやすさと入手しやすさを向上させます。生物学的製剤や注射剤などの先進治療が保険適用となることで、患者の導入が促進され、市場の成長を支えます。経済的障壁を緩和することにより、保険はタイムリーな診断と治療を促し、革新的な骨粗鬆症治療への需要を促進し、市場の可能性を拡大します。例えば、インドのオンライン保険アグリゲーターでありフィンテック・プラットフォームであるPolicyBazaarによると、インドでは定期保険を購入する女性の数が大幅に増加しており、過去2年間で80％増加しています。また、スイス・リーによると、2023年から24年の保険普及率はインドで3.8％、世界では6.5％に達すると予測されています。したがって、医療保険の拡大が骨粗鬆症治療薬市場の成長を牽引しました。

当レポートは、世界の骨粗鬆症治療薬市場について調査し、市場の概要とともに、タイプ別、投与方法別、流通チャネル別、用途別、地域・国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 目次

第3章 表の一覧

第4章 図表一覧

第5章 レポートの構成

第6章 市場の特徴

  • 一般的な市場の定義
  • サマリー
  • 骨粗鬆症治療薬市場の定義とセグメンテーション
  • タイプ別市場セグメンテーション
    • ビスフォスフォネート
    • 選択的エストロゲン受容体モジュレーター（SERM）
    • RANKリガンド阻害剤
    • 副甲状腺ホルモン療法
    • カルシトニン
    • スクレロスチン阻害剤
    • その他
  • 投与方法別市場セグメンテーション
    • 経口
    • 注射
  • 流通チャネル別市場セグメンテーション
    • 小売薬局
    • 病院薬局
    • オンライン販売
  • 用途別の市場セグメンテーション
    • 原発性骨粗鬆症
    • 続発性骨粗鬆症

第7章 主要な市場動向

  • 患者の転帰を改善する革新的な骨粗鬆症治療が発売
  • 革新的なアプローチと規制当局の承認が治療の進歩を推進
  • 骨粗鬆症治療の改善に向けた標的治療オプション別先進治療

第8章 骨粗鬆症治療薬市場- マクロ経済シナリオ

第9章 世界市場の規模と成長

  • 市場規模
  • 市場成長実績、2019年～2024年
  • 市場成長予測、2024年～2029年、2034年

第10章 世界の骨粗鬆症治療薬市場セグメンテーション

  • 世界の骨粗鬆症治療薬市場、タイプ別セグメンテーション、実績および予測、2019年～2024年、2029年予測、2034年予測
  • 世界の骨粗鬆症治療薬市場、投与法別セグメンテーション、実績および予測、2019年～2024年、2029年、2034年
  • 世界の骨粗鬆症治療薬市場、流通チャネル別セグメンテーション、実績および予測、2019年～2024年、2029年予測、2034年予測
  • 世界の骨粗鬆症治療薬市場、用途別セグメンテーション、実績および予測、2019年～2024年、2029年予測、2034年予測

第11章 骨粗鬆症治療薬市場、地域別・国別分析

  • 世界の骨粗鬆症治療薬市場、地域別、実績および予測、2019年～2024年、2029年予測、2034年予測
  • 世界の骨粗鬆症治療薬市場、国別、実績および予測、2019年～2024年、2029年予想、2034年予想

第12章 アジア太平洋市場

第13章 西欧市場

第14章 東欧市場

第15章 北米市場

第16章 南米市場

第17章 中東市場

第18章 アフリカ市場

第19章 競合情勢と企業プロファイル

  • 企業プロファイル
  • Amgen Inc.
  • Eli Lilly and Company
  • Pfizer Inc.
  • Eisai Co., Ltd.
  • Apotex Inc.

第20章 その他の大手企業と革新的企業

  • AbbVie Inc.
  • Novartis AG
  • Sanofi S.A.
  • GSK plc
  • Daiichi Sankyo Company, Limited
  • F. Hoffmann La Roche Ltd.
  • Teva Pharmaceutical Industries Limited
  • Merck & Co. Inc.
  • Radius Health, Inc.
  • Mylan N.V. (Viatris)
  • Sun Pharmaceutical Industries Ltd.
  • UCB Biopharma SRL
  • Dr. Reddy's Laboratories
  • Strides Pharma Science Limited
  • EffRx Pharmaceuticals SA

第21章 競合ベンチマーキング

第22章 競合ダッシュボード

第23章 主要な合併と買収

第24章 機会と戦略

  • 2029年の世界の骨粗鬆症治療薬市場- 最も新たな機会を提供する国
  • 2029年の世界の骨粗鬆症治療薬市場- 最も新たな機会を提供するセグメント
  • 2029年の世界の骨粗鬆症治療薬市場- 成長戦略
    • 市場動向に基づく戦略
    • 競合戦略

第25章 骨粗鬆症治療薬市場、結論・提言

第26章 付録

目次
Product Code: o&s1516

Osteoporosis drugs are medications designed to prevent, treat, or manage osteoporosis-a condition characterized by decreased bone density and increased susceptibility to fractures. The primary goal of these medications is to strengthen bones, reduce bone loss and lower the risk of fractures.

The osteoporosis drugs market consists of sales, by entities (organizations, sole traders, or partnerships), of osteoporosis drugs that are primarily used by individuals diagnosed with osteoporosis, including postmenopausal women, older adults and patients undergoing treatments that affect bone density, such as long-term corticosteroid therapy.

The global osteoporosis drugs market was valued at $11,436.16 million in 2019 which grew till 2024 at a compound annual growth rate (CAGR) of more than 2.00%.

Health Insurance Expansion

During the historic period, the health insurance expansion supported the growth of the osteoporosis drugs market. Health insurance reduces healthcare costs, increasing affordability and access to osteoporosis medications. Coverage for advanced treatments, such as biologics and injectables, incentivizes patient adoption and supports market growth. By alleviating financial barriers, insurance encourages timely diagnosis and treatment, driving demand for innovative osteoporosis therapies and expanding their market potential. For example, according to PolicyBazaar, an Indian online insurance aggregator and fintech platform, the number of women purchasing term insurance plans in India has witnessed significant growth, with an 80% increase over the past two years. Additionally, insurance penetration in 2023-24 is projected to reach 3.8% in India and 6.5% globally according to Swiss Re. Therefore, the health insurance expansion drove the growth of the osteoporosis drugs market.

Innovative Approaches And Regulatory Approvals Driving Treatment Advancements

Companies in the osteoporosis drugs market are prioritizing the development of innovative solutions, such as obtaining regulatory approvals to enhance treatment outcomes. Regulatory approvals refer to official authorization from health agencies, ensuring new treatments meet safety, efficacy and quality standards before market release. For instance, in November 2024, Teva Pharmaceuticals Inc., a US-based pharmaceutical company received U.S. Food and Drug Administration (FDA) approval for generic version of Forteo (teriparatide injection). This generic medication is recommended for postmenopausal women with osteoporosis at high fracture risk who are unable to use alternative treatments. It is also suitable for men with primary or hypogonadal osteoporosis under similar conditions. Additionally, it applies to both men and women experiencing osteoporosis due to long-term glucocorticoid use, again at high fracture risk and unable to use alternative therapies.

The global osteoporosis drugs market is fairly concentrated, with large players operating in the market. The top ten competitors in the market made up to 39.7% of the total market in 2023.

Osteoporosis Drugs Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global osteoporosis drugs market as it emerges from the COVID-19 shut down.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for osteoporosis drugs? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The osteoporosis drugs market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider osteoporosis drugs market; and compares it with other markets.

The report covers the following chapters

  • Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by type, by administration, by distribution channel and by application.
  • Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
  • Macro-Economic Scenario- The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the osteoporosis drugs market.
  • Global Market Size And Growth- Global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
  • Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by type, by administration, by distribution channel and by application in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
  • Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Other Major And Innovative Companies Details on the company profiles of other major and innovative companies in the market.
  • Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
  • Competitive Dashboard- Briefs on competitive dashboard of major players.
  • Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions And Recommendations- This section includes recommendations for osteoporosis drugs providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

  • 1) By Type: Bisphosphonates; Selective Estrogen Receptor Modulators (SERMs); RANK Ligand Inhibitors; Parathyroid Hormone Therapy; Calcitonin; Sclerostin Inhibitor; Other Drug Class
  • 2) By Administration: Oral; Injectable
  • 3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Sales
  • 4) By Application: Primary Osteoporosis; Secondary Osteoporosis
  • Companies Mentioned: Amgen Inc.; Eli Lilly and Company; Pfizer Inc.; Eisai Co., Ltd.; Apotex Inc.
  • Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; UK; Italy; Spain; Russia
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time-series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; osteoporosis drugs indicators comparison.
  • Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

  • 1.1 Osteoporosis Drugs - Market Attractiveness And Macro economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

  • 6.1 General Market Definition
  • 6.2 Summary
  • 6.3 Osteoporosis Drugs Market Definition And Segmentations
  • 6.4 Market Segmentation By Type
    • 6.4.1 Bisphosphonates
    • 6.4.2 Selective Estrogen Receptor Modulators (SERMs)
    • 6.4.3 RANK Ligand Inhibitors
    • 6.4.4 Parathyroid Hormone Therapy
    • 6.4.5 Calcitonin
    • 6.4.6 Sclerostin Inhibitor
    • 6.4.7 Other Drug Class
  • 6.5 Market Segmentation By Administration
    • 6.5.1 Oral
    • 6.5.2 Injectable
  • 6.6 Market Segmentation By Distribution Channel
    • 6.6.1 Retail Pharmacies
    • 6.6.2 Hospital Pharmacies
    • 6.6.3 Online Sales
  • 6.7 Market Segmentation By Application
    • 6.7.1 Primary Osteoporosis
    • 6.7.2 Secondary Osteoporosis

7 Major Market Trends

  • 7.1 Innovative Osteoporosis Treatment Launched To Enhance Patient Outcomes
  • 7.2 Innovative Approaches And Regulatory Approvals Driving Treatment Advancements
  • 7.3 Advance Treatment With Targeted Therapeutic Option For Better Osteoporosis Treatment

8 Osteoporosis Drugs Market - Macro Economic Scenario

  • 8.1 COVID-19 Impact On The Osteoporosis Drugs Market
  • 8.2 Impact Of The War In Ukraine On The Osteoporosis Drugs Market
  • 8.3 Impact Of High Inflation On The Osteoporosis Drugs Market

9 Global Market Size and Growth

  • 9.1 Market Size
  • 9.2 Historic Market Growth, 2019 - 2024, Value ($ Million)
    • 9.2.1 Market Drivers 2019 - 2024
    • 9.2.2 Market Restraints 2019 - 2024
  • 9.3 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
    • 9.3.1 Market Drivers 2024 - 2029
    • 9.3.2 Market Restraints 2024 - 2029

10 Global Osteoporosis Drugs Market Segmentation

  • 10.1 Global Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.2 Global Osteoporosis Drugs Market, Segmentation By Administration, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.3 Global Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 10.4 Global Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

11 Osteoporosis Drugs Market, Regional and Country Analysis

  • 11.1 Global Osteoporosis Drugs Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 11.2 Global Osteoporosis Drugs Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

12 Asia-Pacific Market

  • 12.1 Summary
    • 12.1.1 Market Overview
    • 12.1.2 Region Information
    • 12.1.3 Market Information
    • 12.1.4 Background Information
    • 12.1.5 Government Initiatives
    • 12.1.6 Regulations
    • 12.1.7 Regulatory Bodies
    • 12.1.8 Major Associations
    • 12.1.9 Taxes Levied
    • 12.1.10 Corporate Tax Structure
    • 12.1.11 Investments
    • 12.1.12 Major Companies
  • 12.2 Asia-Pacific Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.3 Asia-Pacific Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.4 Asia-Pacific Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.5 Asia-Pacific Osteoporosis Drugs Market: Country Analysis
  • 12.6 China Market
  • 12.7 Summary
    • 12.7.1 Market Overview
    • 12.7.2 Country Information
    • 12.7.3 Market Information
    • 12.7.4 Background Information
    • 12.7.5 Government Initiatives
    • 12.7.6 Regulations
    • 12.7.7 Regulatory Bodies
    • 12.7.8 Major Associations
    • 12.7.9 Taxes Levied
    • 12.7.10 Corporate Tax Structure
    • 12.7.11 Investments
    • 12.7.12 Major Companies
  • 12.8 China Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.9 China Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.10 China Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.11 India Market
  • 12.12 India Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.13 India Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.14 India Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.15 Japan Market
  • 12.16 Japan Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.17 Japan Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.18 Japan Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.19 Australia Market
  • 12.20 Australia Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.21 Australia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.22 Australia Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.23 Indonesia Market
  • 12.24 Indonesia Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.25 Indonesia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.26 Indonesia Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.27 South Korea Market
  • 12.28 South Korea Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.29 South Korea Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 12.30 South Korea Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Western Europe Market

  • 13.1 Summary
    • 13.1.1 Market Overview
    • 13.1.2 Region Information
    • 13.1.3 Market Information
    • 13.1.4 Background Information
    • 13.1.5 Government Initiatives
    • 13.1.6 Regulations
    • 13.1.7 Regulatory Bodies
    • 13.1.8 Major Associations
    • 13.1.9 Taxes Levied
    • 13.1.10 Corporate tax structure
    • 13.1.11 Investments
    • 13.1.12 Major Companies
  • 13.2 Western Europe Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.3 Western Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.4 Western Europe Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.5 Western Europe Osteoporosis Drugs Market: Country Analysis
  • 13.6 UK Market
  • 13.7 UK Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.8 UK Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.9 UK Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.10 Germany Market
  • 13.11 Germany Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.12 Germany Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.13 Germany Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.14 France Market
  • 13.15 France Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.16 France Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.17 France Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.18 Italy Market
  • 13.19 Italy Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.20 Italy Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.21 Italy Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.22 Spain Market
  • 13.23 Spain Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.24 Spain Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 13.25 Spain Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

14 Eastern Europe Market

  • 14.1 Summary
    • 14.1.1 Market Overview
    • 14.1.2 Region Information
    • 14.1.3 Market Information
    • 14.1.4 Background Information
    • 14.1.5 Government Initiatives
    • 14.1.6 Regulations
    • 14.1.7 Regulatory Bodies
    • 14.1.8 Major Associations
    • 14.1.9 Taxes Levied
    • 14.1.10 Corporate Tax Structure
    • 14.1.11 Investments
    • 14.1.12 Major companies
  • 14.2 Eastern Europe Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.3 Eastern Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.4 Eastern Europe Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.5 Eastern Europe Osteoporosis Drugs Market: Country Analysis
  • 14.6 Russia Market
  • 14.7 Russia Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.8 Russia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 14.9 Russia Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 North America Market

  • 15.1 Summary
    • 15.1.1 Market Overview
    • 15.1.2 Region Information
    • 15.1.3 Market Information
    • 15.1.4 Background Information
    • 15.1.5 Government Initiatives
    • 15.1.6 Regulations
    • 15.1.7 Regulatory Bodies
    • 15.1.8 Major Associations
    • 15.1.9 Taxes Levied
    • 15.1.10 Corporate Tax Structure
    • 15.1.11 Investments
    • 15.1.12 Major Companies
  • 15.2 North America Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.3 North America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.4 North America Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.5 North America Osteoporosis Drugs Market: Country Analysis
  • 15.6 USA Market
  • 15.7 Summary
    • 15.7.1 Market Overview
    • 15.7.2 Country Information
    • 15.7.3 Market Information
    • 15.7.4 Background Information
    • 15.7.5 Government Initiatives
    • 15.7.6 Regulations
    • 15.7.7 Regulatory Bodies
    • 15.7.8 Major Associations
    • 15.7.9 Taxes Levied
    • 15.7.10 Corporate Tax Structure
    • 15.7.11 Investments
    • 15.7.12 Major Companies
  • 15.8 USA Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.9 USA Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.10 USA Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.11 Canada Market
  • 15.12 Canada Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.13 Canada Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 15.14 Canada Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 South America Market

  • 16.1 Summary
    • 16.1.1 Market Overview
    • 16.1.2 Region Information
    • 16.1.3 Market Information
    • 16.1.4 Background Information
    • 16.1.5 Government Initiatives
    • 16.1.6 Regulations
    • 16.1.7 Regulatory Bodies
    • 16.1.8 Major Associations
    • 16.1.9 Taxes Levied
    • 16.1.10 Corporate Tax Structure
    • 16.1.11 Investments
    • 16.1.12 Major Companies
  • 16.2 South America Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.3 South America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.4 South America Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.5 Brazil Market
  • 16.6 Brazil Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.7 Brazil Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 16.8 Brazil Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Middle East Market

  • 17.1 Summary
    • 17.1.1 Market Overview
    • 17.1.2 Region Information
    • 17.1.3 Market Information
    • 17.1.4 Background Information
    • 17.1.5 Government Initiatives
    • 17.1.6 Regulations
    • 17.1.7 Regulatory Bodies
    • 17.1.8 Major Associations
    • 17.1.9 Taxes Levied
    • 17.1.10 Corporate Tax Structure
    • 17.1.11 Investments
    • 17.1.12 Major Companies
  • 17.2 Middle East Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 17.3 Middle East Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 17.4 Middle East Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 Africa Market

  • 18.1 Summary
    • 18.1.1 Market Overview
    • 18.1.2 Region Information
    • 18.1.3 Market Information
    • 18.1.4 Background Information
    • 18.1.5 Government Initiatives
    • 18.1.6 Regulations
    • 18.1.7 Regulatory Bodies
    • 18.1.8 Major Associations
    • 18.1.9 Taxes Levied
    • 18.1.10 Corporate Tax Structure
    • 18.1.11 Investments
    • 18.1.12 Major Companies
  • 18.2 Africa Osteoporosis Drugs Market, Segmentation By Type, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 18.3 Africa Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
  • 18.4 Africa Osteoporosis Drugs Market, Segmentation By Application, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

19 Competitive Landscape And Company Profiles

  • 19.1 Company Profiles
  • 19.2 Amgen Inc.
    • 19.2.1 Company Overview
    • 19.2.2 Products And Services
    • 19.2.3 Financial Overview
  • 19.3 Eli Lilly and Company
    • 19.3.1 Company Overview
    • 19.3.2 Products And Services
    • 19.3.3 Financial Overview
  • 19.4 Pfizer Inc.
    • 19.4.1 Company Overview
    • 19.4.2 Products And Services
    • 19.4.3 Financial Overview
  • 19.5 Eisai Co., Ltd.
    • 19.5.1 Company Overview
    • 19.5.2 Products And Services
    • 19.5.3 Financial Overview
  • 19.6 Apotex Inc.
    • 19.6.1 Company Overview
    • 19.6.2 Products And Services
    • 19.6.3 Business Strategy
    • 19.6.4 Financial Overview

20 Other Major And Innovative Companies

  • 20.1 AbbVie Inc.
    • 20.1.1 Company Overview
    • 20.1.2 Products And Services
  • 20.2 Novartis AG
    • 20.2.1 Company Overview
    • 20.2.2 Products And Services
  • 20.3 Sanofi S.A.
    • 20.3.1 Company Overview
    • 20.3.2 Products And Services
  • 20.4 GSK plc
    • 20.4.1 Company Overview
    • 20.4.2 Products And Services
  • 20.5 Daiichi Sankyo Company, Limited
    • 20.5.1 Company Overview
    • 20.5.2 Products And Services
  • 20.6 F. Hoffmann La Roche Ltd.
    • 20.6.1 Company Overview
    • 20.6.2 Products And Services
  • 20.7 Teva Pharmaceutical Industries Limited
    • 20.7.1 Company Overview
    • 20.7.2 Products And Services
  • 20.8 Merck & Co. Inc.
    • 20.8.1 Company Overview
    • 20.8.2 Products And Services
  • 20.9 Radius Health, Inc.
    • 20.9.1 Company Overview
    • 20.9.2 Products And Services
  • 20.10 Mylan N.V. (Viatris)
    • 20.10.1 Company Overview
    • 20.10.2 Products And Services
  • 20.11 Sun Pharmaceutical Industries Ltd.
    • 20.11.1 Company Overview
    • 20.11.2 Products And Services
  • 20.12 UCB Biopharma SRL
    • 20.12.1 Company Overview
    • 20.12.2 Products And Services
  • 20.13 Dr. Reddy's Laboratories
    • 20.13.1 Company Overview
    • 20.13.2 Products And Services
  • 20.14 Strides Pharma Science Limited
    • 20.14.1 Company Overview
    • 20.14.2 Products And Services
  • 20.15 EffRx Pharmaceuticals SA
    • 20.15.1 Company Overview
    • 20.15.2 Products And Services

21 Competitive Benchmarking

22 Competitive Dashboard

23 Key Mergers And Acquisitions

  • 23.1 Bone Health Technologies Acquired Wellen
  • 23.2 Nestle Health Science Acquired Bountiful Company

24 Opportunities And Strategies

  • 24.1 Global Osteoporosis Drugs Market In 2029 - Countries Offering Most New Opportunities
  • 24.2 Global Osteoporosis Drugs Market In 2029 - Segments Offering Most New Opportunities
  • 24.3 Global Osteoporosis Drugs Market In 2029 - Growth Strategies
    • 24.3.1 Market Trend Based Strategies
    • 24.3.2 Competitor Strategies

25 Osteoporosis Drugs Market, Conclusions And Recommendations

  • 25.1 Conclusions
  • 25.2 Recommendations
    • 25.2.1 Product
    • 25.2.2 Place
    • 25.2.3 Price
    • 25.2.4 Promotion
    • 25.2.5 People

26 Appendix

  • 26.1 Geographies Covered
  • 26.2 Market Data Sources
  • 26.3 Research Methodology
  • 26.4 Currencies
  • 26.5 The Business Research Company
  • 26.6 Copyright and Disclaimer